Working… Menu

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03552471
Recruitment Status : Recruiting
First Posted : June 11, 2018
Last Update Posted : February 25, 2021
ImmunoGen, Inc.
Clovis Oncology, Inc.
Information provided by (Responsible Party):
Floor Backes, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 29, 2021
Estimated Study Completion Date : August 29, 2021